Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 1
2007 1
2010 2
2011 1
2013 2
2014 2
2017 1
2019 1
2020 3
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: pucci f. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study.
Buti S, Perrone F, Zielli T, Mazzaschi G, Casartelli C, Leonetti A, Milanese G, Silva M, Eufrasia Ledda R, Musolino A, Pucci F, Bersanelli M, Tiseo M. Buti S, et al. Among authors: pucci f. Clin Med Insights Oncol. 2021 Sep 8;15:11795549211043427. doi: 10.1177/11795549211043427. eCollection 2021. Clin Med Insights Oncol. 2021. PMID: 34526833 Free PMC article.
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.
Di Bartolomeo M, Raimondi A, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E, Aitini E, Spada F, Rosati G, Marchet A, Pucci F, Zaniboni A, Tamberi S, Pressiani T, Sanna G, Cantore M, Mosconi S, Bolzoni P, Pinto C, Landi L, Soto Parra HJ, Cavanna L, Corallo S, Martinetti A, Hembrough TA, Pietrantonio F. Di Bartolomeo M, et al. Among authors: pucci f. Tumori. 2021 Apr;107(2):150-159. doi: 10.1177/0300891620930803. Epub 2020 Jun 11. Tumori. 2021. PMID: 32522106 Clinical Trial.
Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival.
Ampollini L, Gnetti L, Goldoni M, Viani L, Faedda E, Campanini N, Caruana P, Crafa P, Negri F, Pucci F, Leonardi F, Ventura L, Balestra V, Braggio C, Bocchialini G, Del Rio P, Silini EM, Carbognani P, Rusca M. Ampollini L, et al. Among authors: pucci f. J Thorac Dis. 2017 Oct;9(Suppl 12):S1282-S1290. doi: 10.21037/jtd.2017.07.100. J Thorac Dis. 2017. PMID: 29119016 Free PMC article.
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.
Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, Di Maio M, Fornaro L, Frassineti GL, Granetto C, Iachetta F, Lonardi S, Murialdo R, Ongaro E, Pucci F, Ratti M, Silvestris N, Smiroldo V, Spallanzani A, Strippoli A, Tamberi S, Tamburini E, Zaniboni A, Di Bartolomeo M, Cremolini C, Sposito C, Mazzaferro V, Pietrantonio F. Raimondi A, et al. Among authors: pucci f. Cancers (Basel). 2021 Jun 7;13(11):2839. doi: 10.3390/cancers13112839. Cancers (Basel). 2021. PMID: 34200267 Free PMC article.
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Bongiovanni A, et al. Among authors: pucci f. BMJ Open. 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393. BMJ Open. 2020. PMID: 32690499 Free PMC article.
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F. Bajetta E, et al. Among authors: pucci f. Cancer. 2014 Aug 15;120(16):2457-63. doi: 10.1002/cncr.28726. Epub 2014 Apr 18. Cancer. 2014. PMID: 24752410 Free article. Clinical Trial.
17 results